People
The Novartis Board of Directors is responsible for the direction, strategy, organization and administration of the company. The Board is comprised of 12 members and chaired by Dr. Daniel Vasella.
Board of Directors
Daniel Vasella, M.D.
Chairman and CEO
Read biography:
Ulrich Lehner, Ph.D.
Vice Chairman and Lead Director
Read biography:
Hans-Joerg Rudloff
Vice Chairman
Read biography:
William Brody, M.D., Ph.D.
Read biography:
Srikant Datar, Ph.D.
Read biography:
Ann Fudge
Read biography:
Alexandre F. Jetzer
Read biography:
Pierre Landolt
Read biography:
Andreas von Planta, Ph.D.
Read biography:
Dr. Ing. Wendelin Wiedeking
Read biography:
Marjorie M. Yang
Read biography:
Rolf M. Zinkernagel, M.D.
Read biography:
Corporate governance
We are fully committed to good corporate governance.
Magic Cancer Bullet
In this book, Dr. Vasella recounts the story of our revolutionary cancer drug Glivec/Gleevec.
Company history
Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz.
Our businesses
We offer a wide range of healthcare products in pharmaceuticals, vaccines and diagnostics, generics and consumer health.